Granted Patent
B2
US 9,868,703 · App. 15/276,324 · Granted Jan 16, 2018
PRMT1 inhibitors and uses thereof
Inventors:
Kevin Wayne Kuntz (Woburn, MA); Lorna Helen Mitchell (Cambridge, MA); Gideon Shapiro (Gainesville, FL); Richard Chesworth (Concord, MA); Paula Ann Boriack-Sjodin (Lexington, MA)
Assignee:
Epizyme, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.
Claims (3)
1. A compound that is
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Assignments (3)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME: 051057/0848
Recorded Aug 13, 2022
From: BIOPHARMA CREDIT PLC
To: EPIZYME, INC.
Reel/Frame 061165/0501 →
SECURITY INTEREST
Recorded Nov 19, 2019
From: EPIZYME, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051057/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 3, 2016
From: KUNTZ, KEVIN WAYNE; MITCHELL, LORNA HELEN; SHAPIRO, GIDEON; CHESWORTH, RICHARD; BORIACK-SJODIN, PAULA ANN
To: EPIZYME, INC.
Reel/Frame 039917/0706 →
Continuity (4)
Provisional Application
61781052
· Mar 14, 2013